Corvus Pharmaceuticals (CRVS) to Release Quarterly Earnings on Tuesday

Corvus Pharmaceuticals (NASDAQ:CRVS) is anticipated to post its quarterly earnings results before the market opens on Tuesday, March 18th. Analysts expect Corvus Pharmaceuticals to post earnings of ($0.12) per share for the quarter.

Corvus Pharmaceuticals Price Performance

Shares of NASDAQ:CRVS opened at $4.52 on Friday. Corvus Pharmaceuticals has a 12 month low of $1.30 and a 12 month high of $10.00. The stock has a market cap of $290.44 million, a price-to-earnings ratio of -4.86 and a beta of 0.91. The stock’s 50 day moving average price is $4.86 and its 200 day moving average price is $6.07.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $11.00 price target on shares of Corvus Pharmaceuticals in a report on Tuesday, January 14th. One equities research analyst has rated the stock with a sell rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Corvus Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $12.38.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.